Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Secondary hormonal therapy

¹Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA. dcsmith@umich.edu

Seminars in Urologic Oncology

|February 1, 1997

Summary

This summary is machine-generated.

For metastatic prostate cancer patients progressing to hormone resistance, secondary hormonal therapy offers treatment options when clinical trials are unsuitable. This approach extends primary therapies by reducing androgens and blocking androgen receptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adjuvant and neoadjuvant therapy in prostate cancer.

Seminars in oncology·2001

Same author

Pelvic recurrences post cystectomy: current treatment strategies.

Seminars in urologic oncology·2001

Same author

Toxin entry: how bacterial proteins get into mammalian cells.

Cellular microbiology·2001

Same author

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.

The Journal of urology·2000

Same author

Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens.

Journal of the National Cancer Institute·2000

Same author

A new concept in cancer care: the supportive care program.

The American journal of hospice & palliative care·2000

Same journal

The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies.

Seminars in urologic oncology·2002

Same journal

Poor prognosis germ-cell tumors: An unresolved challenge.

Seminars in urologic oncology·2002

Same journal

Chemotherapy for good-risk germ-cell tumors.

Seminars in urologic oncology·2002

Same journal

Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors.

Seminars in urologic oncology·2002

Same journal

Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?

Seminars in urologic oncology·2002

Same journal

Controversies in the management of testicular seminoma.

Seminars in urologic oncology·2002

See all related articles

Area of Science:

Oncology
Endocrinology

Background:

Metastatic prostate cancer frequently progresses to hormone-refractory disease.
Clinical trials are the preferred treatment for these patients.
Alternative options are needed for patients ineligible for trials.

Purpose of the Study:

To review secondary hormonal therapy concepts for hormone-refractory prostate cancer.
To discuss available and investigational hormonal agents.
To highlight treatment strategies beyond standard clinical trials.

Main Methods:

Review of existing literature on secondary hormonal therapy.
Analysis of mechanisms of action for hormonal agents.
Discussion of clinical approaches including anti-androgen withdrawal.

Related Experiment Videos

Main Results:

Secondary hormonal therapy builds upon primary approaches: androgen suppression and anti-androgen use.
Key concepts include maintaining testicular androgen suppression and understanding anti-androgen withdrawal syndrome.
Several hormonal agents are available, with others under development targeting different mechanisms.

Conclusions:

Secondary hormonal therapy is a viable option for hormone-refractory prostate cancer patients not in clinical trials.
Understanding established and novel hormonal agents is crucial for patient management.
Continued research into new hormonal therapies is essential for improving outcomes.